Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.
Wei DengJinsong YangWenjie NiChen LiXiao ChangWeiming HanZongmei ZhouDongfu ChenQinfu FengJun LiangJima LvXiaozhen WangXin WangLei DengWenqing WangNan BiTao ZhangYexiong LiShugeng GaoQi XueYousheng MaoKelin SunXiangyang LiuDekang FangDali WangJian LiJun ZhaoKang ShaoZhishan LiXinjie ChenLei HanLifang WangJie HeZefen XiaoPublished in: The oncologist (2020)
The value of adjuvant radiotherapy for patients with node-negative esophageal cancer is not clear. The interim results of this phase III study indicated that postoperative radiotherapy significantly improved disease-free survival and decreased local-regional recurrence rate in patients with pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma compared with surgery alone with acceptable toxicities. The distant metastasis rates and overall survival rates were not different between the two groups. Adjuvant radiotherapy should be considered for pathologic T2-3N0M0 thoracic esophageal squamous cell carcinoma. Prospective trials to identify high-risk subgroups are needed.
Keyphrases
- phase iii
- early stage
- free survival
- open label
- locally advanced
- clinical trial
- double blind
- placebo controlled
- phase ii
- spinal cord
- radiation therapy
- radiation induced
- neoadjuvant chemotherapy
- rectal cancer
- lymph node
- squamous cell carcinoma
- minimally invasive
- spinal cord injury
- coronary artery disease
- coronary artery bypass
- atrial fibrillation